Merck KGaA secures CRISPR patents in Japan and Singapore
27-11-2019
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
06-02-2019
Merck granted its first CRISPR patent in Australia
16-06-2017
ralwel / iStockphoto.com
China’s State Intellectual Property Office (SIPO) has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck KGaA, CRISPR, genome editing, CRISPR-Cas9, patent, China’s State Intellectual Property Office
